Surrozen

Yahoo Finance • last month

Surrozen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the und... Full story

Yahoo Finance • 5 months ago

Surrozen GAAP EPS of $0.00, revenue of $6.97M

* Surrozen press release [https://seekingalpha.com/pr/20299421-surrozen-reports-third-quarter-2025-financial-results-and-provides-business-update] (SRZN [https://seekingalpha.com/symbol/SRZN]): Q2 GAAP EPS of $0.00. * Revenue of $6.97M... Full story

Yahoo Finance • 5 months ago

Surrozen Reports Third Quarter 2025 Financial Results and Provides Business Update

SOUTH SAN FRANCISCO, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics that selectively modulate the Wnt pathway for tissue rep... Full story

Yahoo Finance • 5 months ago

Surrozen to Present at Upcoming Healthcare Investor Conference

SOUTH SAN FRANCISCO, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics that selectively modulate the Wnt pathway, with a focus... Full story

Yahoo Finance • 7 months ago

Surrozen Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics that selectively modulate the Wnt pathway, with a focus... Full story

Yahoo Finance • 8 months ago

Surrozen GAAP EPS of $2.55

* Surrozen press release [https://seekingalpha.com/pr/20195253-surrozen-reports-second-quarter-2025-financial-results-and-provides-business-update] (NASDAQ:SRZN [https://seekingalpha.com/symbol/SRZN]): Q2 GAAP EPS of $2.55. * Net: Othe... Full story

Yahoo Finance • 8 months ago

Surrozen Reports Second Quarter 2025 Financial Results and Provides Business Update

Daniel Chao, M.D., Ph.D., joins Surrozen as Vice President of Clinical Development Surrozen forms Clinical Advisory Board comprised of leading retinal specialists Data Presentations at Association for Research in Vision and Ophthalmology... Full story

Yahoo Finance • 11 months ago

Surrozen Granted Patent from U.S. Patent and Trademark Office Directed to Antibody-Based Molecules Targeting Key Receptors in the Wnt Pathway

Newly granted patent is part of the expanding intellectual property portfolio directed to: -generating novel and selective Wnt surrogate molecules with potentially broad therapeutic utility and -incorporating novel discoveries related to... Full story

Yahoo Finance • last year

Surrozen Provides Fourth Quarter and Full Year 2024 Financial Results and Business Updates

SOUTH SAN FRANCISCO, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regen... Full story

Yahoo Finance • 2 years ago

10 Buy-Rated Stocks with Latest Insider Purchases

In this article, we will take a detailed look at the 10 Buy-Rated Stocks with Latest Insider Purchases. For a quick overview of such stocks, read our article5 Buy-Rated Stocks with Latest Insider Purchases. Insider trading and its relatio... Full story

Yahoo Finance • 2 years ago

Surrozen Provides Third Quarter 2023 Financial Results

Expect to announce data from SZN-043 Phase 1a clinical trial in patients with chronic liver disease and in healthy volunteers in Q1 2024 Expect to announce data from SZN-1326 Phase 1a clinical trial in healthy volunteers in Q1 2024 Initi... Full story

Yahoo Finance • 3 years ago

Surrozen Strengthens Board of Directors with the Appointment of Eric Bjerkholt

SOUTH SAN FRANCISCO, Calif., April 05, 2023 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regen... Full story

Yahoo Finance • 3 years ago

Surrozen Provides Fourth Quarter and Full Year 2022 Financial Results and Update on Clinical Pipeline and Corporate Progress

Enrolled first patient in SZN-043 Ph 1a clinical trial in chronic liver disease with data expected by the end of 2023 Expect to begin SZN-043 Ph1b clinical trial in severe alcoholic hepatitis in 2024 with proof-of-concept data expected in... Full story

Yahoo Finance • 3 years ago

Surrozen Reports Third Quarter 2022 Financial Results and Provides Corporate Update

SOUTH SAN FRANCISCO, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regene... Full story

Yahoo Finance • 3 years ago

Surrozen Presents Data on Two Lead Therapeutic Candidates at United European Gastroenterology (UEG) Week

SZN-043 preclinical data shows rapid, transient increases in hepatocyte proliferation and was well tolerated in non-clinical toxicology studies SZN-1326 preclinical data shows improved intestinal epithelial healing, restored epithelial bar... Full story

Yahoo Finance • 4 years ago

Surrozen Reports Second Quarter 2022 Financial Results

Phase 1 clinical trials of SZN-1326 and SZN-043 initiated and ongoing Preclinical proof-of-concept data for multiple programs presented and published in Q2 continue to validate Wnt modulation for tissue repair SOUTH SAN FRANCISCO, Calif.,... Full story

Yahoo Finance • 4 years ago

Surrozen Initiates Dosing in Phase 1 Clinical Trial of SZN-043 for Severe Alcoholic Hepatitis

SZN-043 is a novel hepatocyte-specific R-spondin mimetic bispecific fusion protein targeting ASGR1First part of two-part Phase 1 trial starts in healthy volunteers SOUTH SAN FRANCISCO, Calif., June 13, 2022 (GLOBE NEWSWIRE) -- Surrozen,... Full story

Yahoo Finance • 4 years ago

Surrozen Presents Data on Lead Therapeutic Candidates at Digestive Disease Week (DDW)

SOUTH SAN FRANCISCO, Calif., May 24, 2022 (GLOBE NEWSWIRE) -- Surrozen, Inc. (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, today announced the pre... Full story

Yahoo Finance • 4 years ago

Surrozen Initiates Dosing in Phase 1 Clinical Trial of SZN-1326 for Moderate to Severe Ulcerative Colitis

SZN-1326 is a Fzd5-targeted Wnt-mimetic (SWAP)bi-specific antibody First part of three-part Phase 1/1b trial starts in healthy volunteers SOUTH SAN FRANCISCO, Calif., May 18, 2022 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “C... Full story

Yahoo Finance • 4 years ago

Surrozen Publishes Article in Cellular and Molecular Gastroenterology and Hepatology Demonstrating that SZN-1326, a Selective Wnt Mimetic, Stimulated Robust Colon Epithelial Regeneration and Ameliorated Colitis in an Acute Model of Inflammatory Bowel Disease (IBD)

SOUTH SAN FRANCISCO, Calif., May 16, 2022 (GLOBE NEWSWIRE) -- Surrozen, Inc. (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively modulate the Wnt pathway for tissue repair and regeneration, announced today the pub... Full story